Table 2.
Nueroprotection in Parkinson's disease by selegline (prospective, randomized, double-blind, placebo-controlled studies)
From Riederer and Lachenmayer 2003.
Nueroprotection in Parkinson's disease by selegline (prospective, randomized, double-blind, placebo-controlled studies)
From Riederer and Lachenmayer 2003.